These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30244692)

  • 1. Aim for the core: suitability of the ubiquitin-independent 20S proteasome as a drug target in neurodegeneration.
    Opoku-Nsiah KA; Gestwicki JE
    Transl Res; 2018 Aug; 198():48-57. PubMed ID: 30244692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ubiquitin proteasome system as a potential target for the treatment of neurodegenerative diseases.
    Ying Z; Wang H; Wang G
    Curr Pharm Des; 2013; 19(18):3305-14. PubMed ID: 23151138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rpt5-Derived Analogs Stimulate Human Proteasome Activity in Cells and Degrade Proteins Forming Toxic Aggregates in Age-Related Diseases.
    Cekała K; Trepczyk K; Witkowska J; Jankowska E; Wieczerzak E
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Syrosingopine Enhances 20S Proteasome Activity and Degradation of α-Synuclein.
    Sadahiro Y; Nishimura S; Hitora Y; Tsukamoto S
    J Nat Prod; 2024 Mar; 87(3):554-559. PubMed ID: 37938154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linkage between the proteasome pathway and neurodegenerative diseases and aging.
    Vigouroux S; Briand M; Briand Y
    Mol Neurobiol; 2004 Oct; 30(2):201-21. PubMed ID: 15475627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the 26S Proteasome To Protect Against Proteotoxic Diseases.
    Myeku N; Duff KE
    Trends Mol Med; 2018 Jan; 24(1):18-29. PubMed ID: 29233753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulating the 20S proteasome ubiquitin-independent degradation pathway.
    Ben-Nissan G; Sharon M
    Biomolecules; 2014 Sep; 4(3):862-84. PubMed ID: 25250704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ubiquitin-proteasome system in neurodegeneration.
    McKinnon C; Tabrizi SJ
    Antioxid Redox Signal; 2014 Dec; 21(17):2302-21. PubMed ID: 24437518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dihydroquinazolines enhance 20S proteasome activity and induce degradation of α-synuclein, an intrinsically disordered protein associated with neurodegeneration.
    Fiolek TJ; Magyar CL; Wall TJ; Davies SB; Campbell MV; Savich CJ; Tepe JJ; Mosey RA
    Bioorg Med Chem Lett; 2021 Mar; 36():127821. PubMed ID: 33513387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers.
    Fiolek TJ; Keel KL; Tepe JJ
    ACS Chem Neurosci; 2021 Apr; 12(8):1438-1448. PubMed ID: 33788542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
    Thibaudeau TA; Anderson RT; Smith DM
    Nat Commun; 2018 Mar; 9(1):1097. PubMed ID: 29545515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment of human multiple myeloma cells with bortezomib and doxorubicin alters the interactome of 20S proteasomes.
    Mittenberg AG; Kuzyk VO; Shabelnikov SV; Gorbach DP; Shatrova AN; Fedorova OA; Barlev NA
    Cell Cycle; 2018; 17(14):1745-1756. PubMed ID: 30009671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
    Coleman RA; Muli CS; Zhao Y; Bhardwaj A; Newhouse TR; Trader DJ
    Bioorg Med Chem Lett; 2019 Feb; 29(3):420-423. PubMed ID: 30587447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cyclophilin-like domain of Ran-binding protein-2 modulates selectively the activity of the ubiquitin-proteasome system and protein biogenesis.
    Yi H; Friedman JL; Ferreira PA
    J Biol Chem; 2007 Nov; 282(48):34770-8. PubMed ID: 17911097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small Molecule Modulation of Proteasome Assembly.
    Njomen E; Osmulski PA; Jones CL; Gaczynska M; Tepe JJ
    Biochemistry; 2018 Jul; 57(28):4214-4224. PubMed ID: 29897236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ubiquitin-like modifier FAT10 is degraded by the 20S proteasome in vitro but not in cellulo.
    Oliveri F; Keller SJ; Goebel H; Alvarez Salinas GO; Basler M
    Life Sci Alliance; 2023 Jun; 6(6):. PubMed ID: 37012049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluation of Potent 20S Proteasome Activators for the Potential Treatment of α-Synucleinopathies.
    Staerz SD; Jones CL; Tepe JJ
    J Med Chem; 2022 May; 65(9):6631-6642. PubMed ID: 35476454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of the ubiquitin-proteasome system as drug targets.
    Kar G; Keskin O; Fraternali F; Gursoy A
    Curr Pharm Des; 2013; 19(18):3175-89. PubMed ID: 23151131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.